Novavax (NVAX, $124.43) reports lower-than-expected Q2 revenue
Novavax reported revenue that increased substantially year-over-year, but was lower than analysts' expectations.
The vaccine development company’s revenue of $35.5 million in the latest quarter, compared to $3.4 million in the year-ago quarter. But the revenue was lower than Wall Street expectations.
During the quarter, the company experienced loss of -$17.5 million, or -30 cents a share share, compared to a net loss of -$39.6 million, or -$1.69 a share for the second quarter of 2019.
Research and development expenses climbed 15% to $34.8 million, primarily due to increased development activities relating to the coronavirus vaccine NVX-CoV2373, according to the company.
Last Friday, Novavax and Japanese drug company Takeda announced a partnership to develop, produce and commercialize Novavax's coronavirus-vaccine candidate in Japan.
According to Tickeron, NVAX's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram just turned negative
This is a Bearish indicator signaling NVAX's price could decline. Traders may explore shorting the ticker or looking at put options. In 38 of 39 cases where NVAX's MACD histogram became negative, the price fell further within the following month. The odds of a continued Downtrend are 90%.
Current price $124.43 is above $44.60 the highest support line found by A.I. Throughout the month of 07/10/20 - 08/11/20, the price experienced a +58% Uptrend, while the week of 08/04/20 - 08/11/20 shows a -5% Downtrend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator appears to be shifting from an Uptrend to a Downtrend. In 30 of 38 cases where NVAX's RSI indicator exited the overbought zone, the price fell further within the following month. The odds of a continued Downtrend are 79%.
The Stochastic Indicator may be shifting from an Uptrend to a Downtrend. In 46 of 54 cases where NVAX's Stochastic indicator exited the overbought zone, the price fell further within the following month. The odds of a continued Downtrend are 85%.
The higher Bollinger Band was broken -- a price fall is expected as the ticker heads toward the middle band, which invites the trader to consider selling or shorting the ticker, or exploring put options. In 35 of 41 cases where NVAX's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 85%.
Bullish Trend Analysis
The Aroon Indicator entered an Uptrend today. In 128 of 143 similar cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 71%. During the last month, the daily ratio of advancing to declining volumes was 1.85 to 1.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (49.59) is normal, around the industry mean (82.86). P/E Ratio (0.00) is within average values for comparable stocks, (78.26). Projected Growth (PEG Ratio) (0.00) is also within normal values, averaging (5.23). Dividend Yield (0.00) settles around the average of (0.08) among similar stocks. P/S Ratio (97.25) is also within normal values, averaging (1454.81).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
NVAX's Stochastic Oscillator is staying in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NVAX's RSI Indicator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
NVAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 157 cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on December 20, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on NVAX as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on December 27, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 50-day moving average for NVAX moved below the 200-day moving average on December 04, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (15.297). P/E Ratio (0.000) is within average values for comparable stocks, (87.398). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.754). NVAX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (1.358) is also within normal values, averaging (262.078).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a company which engages in development of novel recombinant vaccines
Industry Biotechnology